☆ 4.6 Review

EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?

CANCERS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial

Margarita Majem et al.

Summary: This study demonstrated that adjuvant osimertinib treatment maintained health-related quality of life in patients with completely resected EGFR-mutated non-small cell lung cancer, with no clinically meaningful differences compared to placebo.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected EGFR-mutated non-small-cell lung cancer: a meta-analysis

Meichen Li et al.

Summary: Adjuvant EGFR tyrosine kinase inhibitors significantly improved disease-free survival and nonsignificantly improved overall survival in resected EGFR-mutated NSCLC. Different treatment regimes, treatment duration, tumor stage, and EGFR mutation type may impact the efficacy of EGFR inhibitors in these post-surgery patients.

FUTURE ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT)

Hirohito Tada et al.

Summary: The efficacy of gefitinib as an adjuvant therapy for non-small-cell lung cancer patients with EGFR mutation was investigated in this study. The results showed that although gefitinib appeared to prevent early relapse, it did not prolong disease-free survival or overall survival. However, in certain patient subsets, adjuvant gefitinib may be justified.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Gefitinib as neoadinvant therapy for resectahle stage II-IIIA non-small cell lung cancer: A phase II study

Yang Zhang et al.

Summary: The study aimed to investigate the efficacy and safety of neoadjuvant gefitinib in patients with stage II-IIIA NSCLC. The results showed that neoadjuvant therapy with gefitinib was safe and may be a viable treatment option for these patients, with potential for improved survival in those with major pathologic response.

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2021)

添加到收藏夹

Review Surgery

Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Dong Chen et al.

Summary: The study found through meta-analysis that neoadjuvant targeted therapy significantly increases objective response rate and reduces grade 3/4 adverse events compared to neoadjuvant chemotherapy in EGFR mutation-positive stage IIIA NSCLC patients. Although overall survival is slightly higher in the NTT group, the difference was not significant, and there was no significant difference in progression-free survival.

FRONTIERS IN SURGERY (2021)

添加到收藏夹

Article Oncology

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Wen-Zhao Zhong et al.

Summary: The adjuvant therapy with gefitinib in early-stage NSCLC patients with EGFR mutation showed improved DFS compared to standard chemotherapy, although this did not translate into a significant OS difference. However, the OS with adjuvant gefitinib was one of the longest observed in this patient group when compared with historic data.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Editorial Material Oncology

ADAURA: Mature Enough for Publication, Not for Prime Time

Alfredo Addeo et al.

Summary: This commentary discusses the challenges of using suboptimal endpoints to justify expedited approval of new drug therapies.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Gregory J. Riely et al.

Summary: Mobocertinib, an oral EGFR inhibitor targeting EGFR gene mutations in non-small cell lung cancer, demonstrated antitumor activity with manageable toxicity in patients with EGFRex20ins mutations in this study, supporting further development in this patient population.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis

Chutong Lin et al.

Summary: In early-stage NSCLC patients, adjuvant EGFR-TKIs show better efficacy and safety compared to chemotherapy. Treatment duration, mutation types, and drug selection can affect the degree of benefit for EGFR mutation-positive patients.

THORACIC CANCER (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Si-Yang Liu et al.

Summary: The ADJUVANT study demonstrated the superiority of adjuvant gefitinib over chemotherapy in disease-free survival of resected EGFR-mutant NSCLC patients. By identifying predictive genomic signatures, the study proposed a potential stratification method to guide personalized adjuvant therapy selection for patients.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Oncology

Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis

Yi Zhao et al.

Summary: EGFR-TKIs are commonly used treatments for lung cancer, with distinct toxicity profiles among different drugs. Studies suggest greater toxicity for dacomitinib and afatinib, and relatively higher safety for icotinib.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

添加到收藏夹

Article Oncology

Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Adjuvant Setting for Patients with Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer: A Meta-Analysis with 11 Trials

Qifan Yin et al.

Summary: This study conducted a meta-analysis to evaluate the role of EGFR-TKI treatment in the adjuvant setting for patients with resected EGFR-mutant NSCLC. The results showed that EGFR-TKI treatment significantly improved DFS and OS compared to non-EGFR-TKI treatment in this setting. Further large-scale and well-designed clinical trials are needed to confirm these findings.

ONCOLOGY RESEARCH AND TREATMENT (2021)

添加到收藏夹

Review Oncology

Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients

Rui-Lian Chen et al.

Summary: This meta-analysis demonstrates that adjuvant EGFR-TKI therapy could significantly prolong DFS in patients with resected EGFR-mutant NSCLC. Treatment with osimertinib showed improved DFS with a lower risk of brain recurrence than treatment with gefitinib or erlotinib for resected disease.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Oncology

FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review

Abigail L. Koch et al.

Summary: Osimertinib was approved by the FDA as adjuvant therapy for non-small cell lung cancer patients with specific mutations, based on the positive results from the ADAURA study. The approval marks a significant advancement in the targeted treatment of NSCLC.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA

Masahiro Tsuboi et al.

Summary: The NeoADAURA study aims to evaluate the efficacy of neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in patients with resectable EGFR mutation-positive NSCLC. The primary endpoint is centrally assessed major pathological response at the time of resection, while secondary endpoints include event-free survival, pathological complete response, and nodal downstaging at the time of surgery.

FUTURE ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial.

Hirohito Tada et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Cost evaluation of adjunctive osimertinib use in resected epidermal growth factor receptor-positive non-small cell lung cancer.

Briana Choi et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.

Christopher Lemmon et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Critical Care Medicine

Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

Jianxing He et al.

Summary: This study compared the efficacy of icotinib and chemotherapy in patients with EGFR-mutant stage II-IIIA NSCLC after complete tumor resection. The results showed that compared to chemotherapy, icotinib significantly improved disease-free survival and had better tolerability in this patient population.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Oncology

The Reality of Lung Cancer Paradox: The Impact of Body Mass Index on Long-Term Survival of Resected Lung Cancer. A French Nationwide Analysis from the Epithor Database

Marco Alifano et al.

Summary: The study assessed the prognostic role of preoperative BMI on survival in NSCLC patients undergoing lung resection, finding that obesity may have a protective effect for patients with lung cancer. Obese patients had improved survival compared to normal weight and underweight patients, with BMI being a strong and independent predictor of survival in NSCLC patients undergoing surgery.

CANCERS (2021)

添加到收藏夹

Review Oncology

Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review

Zhe Zhang et al.

Summary: The study identified substantial inconsistencies in recommendations across global NSCLC guidelines, particularly in diagnosis and treatment, involving various topics. Targeted therapy and immunotherapy for specific gene mutations were the main treatment recommendations, but variations were observed in treatment choices.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer

Joel W. Neal et al.

Summary: This study investigated the impact of different durations of adjuvant therapy on recurrence rates in patients with EGFR-mutant non-small-cell lung cancer. The results showed a lower recurrence rate and longer median recurrence-free survival in the 2-year group compared to the 3-month group.

JCO PRECISION ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Jang Ho Cho et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Yi-Long Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial

Kenji Suzuki et al.

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2019)

添加到收藏夹

Article Oncology

EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations

Wenjie Tang et al.

LUNG CANCER (2019)

添加到收藏夹

Article Oncology

A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer

Hua Cheng et al.

LUNG CANCER (2019)

添加到收藏夹

Article Oncology

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer

Nathan A. Pennell et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, Research & Experimental

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients

Liwen Xiong et al.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2019)

添加到收藏夹

Review Oncology

Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC) A Systematic Review and Meta-analysis

Jacques Raphael et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2019)

添加到收藏夹

Editorial Material Oncology

For a better adjuvant strategy for resected lung cancer-lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104)

Kenichi Suda

TRANSLATIONAL LUNG CANCER RESEARCH (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Simon Vyse et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)

添加到收藏夹

Review Public, Environmental & Occupational Health

Global Epidemiology of Lung Cancer

Julie A. Barta et al.

ANNALS OF GLOBAL HEALTH (2019)

添加到收藏夹

Article Oncology

Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study

Hounai Xie et al.

CLINICAL LUNG CANCER (2018)

添加到收藏夹

Letter Oncology

Quality of life comparing carboplatin with cisplatin in the treatment of non-small cell lung cancer

Michael Snee

EUROPEAN JOURNAL OF CANCER (2018)

添加到收藏夹

Article Oncology

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen-Zhao Zhong et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Critical Care Medicine

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN) a randomised, open-label, phase 2 trial

Dongsheng Yue et al.

LANCET RESPIRATORY MEDICINE (2018)

添加到收藏夹

Article Biotechnology & Applied Microbiology

EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials

Jing-Xun Wu et al.

ONCOTARGETS AND THERAPY (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry

Robert Dziedzic et al.

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2017)

添加到收藏夹

Review Oncology

Neoadjuvant and adjuvant therapy for Stage III non-small cell lung cancer

Shun-ichi Watanabe et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Review Oncology

Uncommon EGFR mutations in advanced non-small cell lung cancer

Grainne M. O'Kane et al.

LUNG CANCER (2017)

添加到收藏夹

Article Medicine, General & Internal

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer

T. S. Mok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Respiratory System

Disease-free survival improved by use of adjuvant EGFR tyrosine kinase inhibitors in resectable non-small cell lung cancer: an updated meta-analysis

Yonggang Yuan et al.

JOURNAL OF THORACIC DISEASE (2017)

添加到收藏夹

Article Critical Care Medicine

The Eighth Edition Lung Cancer Stage Classification

Frank C. Detterbeck et al.

CHEST (2017)

添加到收藏夹

Review Oncology

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

Yoshihisa Kobayashi et al.

CANCER SCIENCE (2016)

添加到收藏夹

Article Critical Care Medicine

Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis

Qingyuan Huang et al.

CHEST (2016)

添加到收藏夹

Review Oncology

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer

Ramaswamy Govindan et al.

CLINICAL CANCER RESEARCH (2015)

添加到收藏夹

Article Oncology

A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?

Chao Lv et al.

CLINICAL LUNG CANCER (2015)

添加到收藏夹

Article Oncology

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Karen Kelly et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis

Chee Khoon Lee et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Wenzhao Zhong et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy

Siyang Feng et al.

PLOS ONE (2015)

添加到收藏夹

Article Oncology

Pemetrexed-Carboplatin Adjuvant Chemotherapy With or Without Gefitinib in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Harbouring EGFR Mutations: A Randomized, Phase II Study

Ning Li et al.

ANNALS OF SURGICAL ONCOLOGY (2014)

添加到收藏夹

Review Oncology

Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials

Liang Shi et al.

LUNG CANCER (2014)

添加到收藏夹

Article Oncology

Gefitinib Versus Placebo in Completely Resected Non-Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study

Glenwood D. Goss et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Review Oncology

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

Hiroyuki Yasuda et al.

LANCET ONCOLOGY (2012)

添加到收藏夹

Article Respiratory System

The Role of Lymphadenectomy in Lung Cancer Surgery

Antonio D'Andrilli et al.

THORACIC SURGERY CLINICS (2012)

添加到收藏夹

Review Pathology

EGFR Mutations and Lung Cancer

Gilda da Cunha Santos et al.

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)

添加到收藏夹

Article Oncology

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer

Jose Rodrigues-Pereira et al.

JOURNAL OF THORACIC ONCOLOGY (2011)

添加到收藏夹

Article Oncology

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations

Yelena Y. Janjigian et al.

JOURNAL OF THORACIC ONCOLOGY (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer

Michael J. Eck et al.

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)

添加到收藏夹

Article Oncology

Successful Erlotinib Rechallenge after Gefitinib-Induced Acute Interstitial Pneumonia

Shih-Chieh Chang et al.

JOURNAL OF THORACIC ONCOLOGY (2010)

添加到收藏夹

Article Oncology

Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group

Jean-Pierre Pignon et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

添加到收藏夹

Review Oncology

Epidermal growth factor receptor mutations in lung cancer

Sreenath V. Sharma et al.

NATURE REVIEWS CANCER (2007)

添加到收藏夹

Article Oncology

Epidermal growth factor receptor mutation testing in the care of lung cancer patients

Lecia V. Sequist et al.

CLINICAL CANCER RESEARCH (2006)

添加到收藏夹

Article Oncology

Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer

M Tsuboi et al.

ANTI-CANCER DRUGS (2005)

添加到收藏夹

Article Medicine, General & Internal

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

N Thatcher et al.

LANCET (2005)

添加到收藏夹

Article Medicine, General & Internal

Severe acute interstitial pneumonia and gefitinib

A Inoue et al.

LANCET (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.